{
    "Clinical Trial ID": "NCT00082433",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ixabepilone + Capecitabine",
        "  Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.",
        "INTERVENTION 2: ",
        "  Capecitabine",
        "Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest."
    ],
    "Eligibility": [
        "Patients must have received prior treatment which included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).",
        "  Patients must have received no more than two prior chemotherapy regimens. Patients who have not received treatment for metastatic disease must have relapsed within one year.",
        "  Patients may not have any history of brain and/or leptomeningeal metastases.",
        "  Patients may not have Grade 2 or worse neuropathy at the time of study entry.",
        "  Patients may not have had prior treatment with any epothilones and/or capecitabine (i.e. Xeloda)"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Overall Survival (OS)",
        "  Overall survival was defined as the time in months from randomization until the date of death. For those patients who had not died, survival duration was censored at the last date the patient was known to be alive. Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method.",
        "  Time frame: from date of randomization until death",
        "Results 1: ",
        "  Arm/Group Title: Ixabepilone + Capecitabine",
        "  Arm/Group Description: Ixabepilone in combination with capecitabine (combination group): Ixabepilone 40 mg/m2 administered as a 3-hour intravenous (IV) infusion on Day 1 of each cycle only, plus oral capecitabine 1000 mg/m2 twice a day (BID) (2000 mg/m2 daily dose) x 14 days, followed by 1 week of rest.",
        "  Overall Number of Participants Analyzed: 609",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  16.39        (14.95 to 17.91)",
        "Results 2: ",
        "  Arm/Group Title: Capecitabine",
        "  Arm/Group Description: Capecitabine alone: Capecitabine 1250 mg/m2 BID (2500 mg/m2 daily dose) x 14 days, followed by 1 week of rest.",
        "  Overall Number of Participants Analyzed: 612",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: months  15.64        (13.86 to 17.02)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 192/603 (31.84%)",
        "  ANAEMIA 5/603 (0.83%)",
        "  LEUKOPENIA 1/603 (0.17%)",
        "  NEUTROPENIA 8/603 (1.33%)",
        "  LYMPH NODE PAIN 0/603 (0.00%)",
        "  THROMBOCYTOPENIA 3/603 (0.50%)",
        "  FEBRILE NEUTROPENIA 5/603 (0.83%)",
        "  PERICARDITIS 1/603 (0.17%)",
        "  ANGINA UNSTABLE 0/603 (0.00%)",
        "  CARDIAC FAILURE 0/603 (0.00%)",
        "  SINUS TACHYCARDIA 0/603 (0.00%)",
        "  ATRIAL FIBRILLATION 2/603 (0.33%)",
        "Adverse Events 2:",
        "  Total: 205/595 (34.45%)",
        "  ANAEMIA 7/595 (1.18%)",
        "  LEUKOPENIA 8/595 (1.34%)",
        "  NEUTROPENIA 18/595 (3.03%)",
        "  LYMPH NODE PAIN 1/595 (0.17%)",
        "  THROMBOCYTOPENIA 4/595 (0.67%)",
        "  FEBRILE NEUTROPENIA 34/595 (5.71%)",
        "  PERICARDITIS 0/595 (0.00%)",
        "  ANGINA UNSTABLE 1/595 (0.17%)",
        "  CARDIAC FAILURE 1/595 (0.17%)",
        "  SINUS TACHYCARDIA 2/595 (0.34%)",
        "  ATRIAL FIBRILLATION 0/595 (0.00%)"
    ]
}